OncoSec Medical Incorporated Stock News

Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share. EUDA Health Holdings Limited (NASDAQ: EUDA) shares climbed 37% to c

Low-float stocks can do strange and unexpected things sometimes. That's as valid an explanation as any for the unusual price movement in OncoSec Medical (NASDAQ: ONCS ) stock today.

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Techn

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. TaskUs, Inc. (NAS

OncoSec Medical Incorporated (ONCS) has appointed George Chi as Chief Financial Officer. Mr

OncoSec Medical Inc (ONCS) shares closed today 13.8% higher than it did at the end of yesterday. The stock is currently down 10.3% year-to-date, down 86.7% over the past 12 months, and down 93.4% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $1.07 and as low as $0.82 this week.Shares closed 88.0% below its 52-week high and 22.5% above its 52-week low.Trading volume this week was 26.8% lower than the 10-day average and 68.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 93.7% The company's stock price performance over the past 12 months lags the peer average by 116.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PENNINGTON, N.J. and SAN DIEGO , Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS ) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body''s immune system to target and attack cancer, today announced that Margaret Dalesandro , Ph.D., Chair of the Board of Directors and member of the Leadership Committee, has resigned from the Board of Directors and the Leadership Committee, effective immediately, and Dr. Linda Shi , M.D., Ph.D., has been added to the OncoSec Board of Directors and appointed Chair. Kevin Smith remarked, "On behalf of the Board of Directors, we are grateful to Margaret for her leadership, expert guidance, and commitment to the company, particularly over the last six months stepping into her active role on the Leadership Committee. We would like to thank Margaret for her dedication to the company." Dr. Linda Shi is the deputy president and Chief Medical officer of Grand Pharma ( China ), as well as an Executive Director of Grand Pharmaceutical Group Limited, a publicly listed company in Hong Kong .

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.12, Fidelity Earnings reports. Shares of ONCS traded up $0.01 during mid-day trading on Thursday, hitting $1.23. 4,172 shares of the company traded hands, compared to its []

OncoSec Medical (NASDAQ:ONCS) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12, Fidelity Earnings reports. ONCS traded up $0.02 on Thursday, hitting $1.24. The company had a trading volume of 3,923 shares, compared to its average volume of 625,943. The […]

State Street Corp purchased a new stake in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) in the second quarter, HoldingsChannel reports. The institutional investor purchased 19,929 shares of the biotechnology companys stock, valued at approximately $56,000. Several other large investors also recently made changes to their positions in the company. Millennium Management LLC lifted its holdings []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome Acadia Pharmaceuticals Inc. (N

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Regulus Therapeutics (NASDAQ:RGLS) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Insider & Institutional Ownership 26.3% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, []

Virtu Financial LLC acquired a new position in shares of OncoSec Medical Incorporated (NASDAQ:ONCS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,649 shares of the biotechnology company’s stock, valued at approximately $36,000. Several other large investors have also […]